Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.

Hope W, Johnstone G, Cicconi S, Felton T, Goodwin J, Whalley S, Santoyo-Castelazo A, Ramos-Martin V, Lestner J, Credidio L, Dane A, Carr DF, Pirmohamed M, Salim R, Neely M.

Antimicrob Agents Chemother. 2019 Mar 27;63(4). pii: e02353-18. doi: 10.1128/AAC.02353-18. Print 2019 Apr.

2.

Repurposing and Reformulation of the Antiparasitic Agent Flubendazole for Treatment of Cryptococcal Meningoencephalitis, a Neglected Fungal Disease.

Nixon GL, McEntee L, Johnson A, Farrington N, Whalley S, Livermore J, Natal C, Washbourn G, Bibby J, Berry N, Lestner J, Truong M, Owen A, Lalloo D, Charles I, Hope W.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e01909-17. doi: 10.1128/AAC.01909-17. Print 2018 Apr.

3.

Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy.

Zimmerman M, Lestner J, Prideaux B, O'Brien P, Dias-Freedman I, Chen C, Dietzold J, Daudelin I, Kaya F, Blanc L, Chen PY, Park S, Salgame P, Sarathy J, Dartois V.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00924-17. doi: 10.1128/AAC.00924-17. Print 2017 Sep.

4.

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis.

Lestner J, McEntee L, Johnson A, Livermore J, Whalley S, Schwartz J, Perfect JR, Harrison T, Hope W.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00090-17. doi: 10.1128/AAC.00090-17. Print 2017 Jun.

5.

Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, Wood LV, Jarosinski PF, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7340-7346. doi: 10.1128/AAC.01427-16. Print 2016 Dec.

6.

Vancomycin toxicity in neonates: a review of the evidence.

Lestner JM, Hill LF, Heath PT, Sharland M.

Curr Opin Infect Dis. 2016 Jun;29(3):237-47. doi: 10.1097/QCO.0000000000000263. Review.

PMID:
26895572
7.

Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.

Lestner JM, Versporten A, Doerholt K, Warris A, Roilides E, Sharland M, Bielicki J, Goossens H; ARPEC Project Group.

Antimicrob Agents Chemother. 2015 Feb;59(2):782-9. doi: 10.1128/AAC.04109-14. Epub 2014 Nov 17.

8.

Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Barker CI, Germovsek E, Hoare RL, Lestner JM, Lewis J, Standing JF.

Adv Drug Deliv Rev. 2014 Jun;73:127-39. doi: 10.1016/j.addr.2014.01.002. Epub 2014 Jan 17. Review.

9.

Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections.

Lestner J, Hope WW.

Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):911-26. doi: 10.1517/17425255.2013.794785. Epub 2013 May 6. Review.

PMID:
23641752
10.

Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.

Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK Jr, Hope WW.

Br J Clin Pharmacol. 2013 Jun;75(6):1381-95. doi: 10.1111/bcp.12025. Review.

11.

Delineating the 17q24.2-q24.3 microdeletion syndrome phenotype.

Lestner JM, Ellis R, Canham N.

Eur J Med Genet. 2012 Dec;55(12):700-4. doi: 10.1016/j.ejmg.2012.08.003. Epub 2012 Aug 24.

PMID:
22982078
12.

Unusual neuroradiological features in Schinzel-Giedion syndrome: a novel case.

Lestner JM, Chong WK, Offiiah A, Kefas J, Vandersteen AM.

Clin Dysmorphol. 2012 Jul;21(3):152-4. doi: 10.1097/MCD.0b013e3283518f1e. No abstract available.

PMID:
22473152
13.

Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

Lestner JM, Baburaj R, Edwards CM.

Br J Hosp Med (Lond). 2011 Jul;72(7):412-3. No abstract available.

PMID:
21841617
14.

Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy.

Howard SJ, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya JB, Warn PA, Hope WW.

J Infect Dis. 2011 May 1;203(9):1324-32. doi: 10.1093/infdis/jir023. Epub 2011 Feb 28.

15.

Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis.

Lestner JM, Howard SJ, Goodwin J, Gregson L, Majithiya J, Walsh TJ, Jensen GM, Hope WW.

Antimicrob Agents Chemother. 2010 Aug;54(8):3432-41. doi: 10.1128/AAC.01586-09. Epub 2010 May 3.

16.

Tremor: a newly described adverse event with long-term itraconazole therapy.

Lestner JM, Denning DW.

J Neurol Neurosurg Psychiatry. 2010 Mar;81(3):327-9. doi: 10.1136/jnnp.2009.174706.

PMID:
20185472
17.

Toxicodynamics of itraconazole: implications for therapeutic drug monitoring.

Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW.

Clin Infect Dis. 2009 Sep 15;49(6):928-30. doi: 10.1086/605499.

PMID:
19681707
18.

Therapeutic drug monitoring for triazoles.

Hope WW, Billaud EM, Lestner J, Denning DW.

Curr Opin Infect Dis. 2008 Dec;21(6):580-6. doi: 10.1097/QCO.0b013e3283184611. Review.

PMID:
18978525

Supplemental Content

Loading ...
Support Center